Gene Therapy Death Raises Ethical Issues
By Marcy Darnovsky,
San Francisco Chronicle
| 09. 13. 2007
Later this month, a committee of the National Institutes of Health will discuss the recent death of 36-year-old Illinois resident Jolee Mohr in an experimental gene therapy study sponsored by Targeted Genetics Corporation. The NIH committee is an advisory body only, but its meeting may provide Mohr's family - and the rest of us - a rare glimpse into the inner workings of the clinical trial enterprise in the United States.
Real regulatory and oversight authority for gene therapy and other clinical trials rests with the Food and Drug Administration. The FDA conducts much of its work behind closed doors in order to protect the proprietary interests of the studies' sponsors. The unfortunate result is a deficit of transparency and accountability, and an unknowable amount of dirty linen hidden away.
The FDA is investigating Mohr's death, and hasn't yet announced whether it will be attributed to the gene transfer. But Mohr died following a fever of 105 degrees and multiple organ failure, symptoms that began to develop just after she was injected with the genes carried by engineered viruses.
Gene...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Mesha Maren , Salon | 07.20.2024